登录新浪财经APP 搜索【信披】查看更多考评等级 一、股东会审议通过权益分派方案情况 （一）2026年2月9日，公司2025年度股东会审议通过了《公司 2025年度利润分配预案》（以下简称利 润分配方案）。根据该方案，公司以截至2025年12月31日总股本577,209,600股为基数，向全体股东每10 股派发现金红利1.46元（含税），共计派发现金红利84,272,601.60元（含税），不送红股，不以公积金 转增股本。如果自2025年12月31日至权益分派实施公告确定的股权登记日前，公司总股本发生变动的， 公司将按照分红总金额不变的原则，相应调整每股分红额。 （二）自利润分配方案披露至实施期间，公司股本总额未发生变化，因此分配红利总金额及分配比例均 不变。 （三）本次实施的权益分派方案与公司2025年度股东会审议通过的利润分配方案一致。 （四）本次实施的权益分派方案距公司2025年度股东会审议通过的时间未超过两个月。 二、本次实施的权益分派方案 公司2025年年度权益分派方案为：以577,209,600股为基数，向全体股东每10股派发现金红利1.46元（含 税；扣税后，QFII、RQFII以及持有首发前限 ...

证券日报网讯 2月26日，沃华医药发布2025年度权益分派实施公告称，公司2025年度权益分派方案为每 10股派发现金红利1.46元（含税），股权登记日为2026年3月4日，除息日为2026年3月5日。 （编辑 任世碧） ...

证券代码：002107 证券简称：沃华医药 公告编号：2026-014 （一）2026 年 2 月 9 日，公司 2025 年度股东会审议通过了《公 司 2025 年度利润分配预案》（以下简称利润分配方案）。根据该方案， 公司以截至 2025 年 12 月 31 日总股本 577,209,600 股为基数，向全体 股东每 10 股派发现金红利 1.46 元（含税），共计派发现金红利 84,272,601.60 元（含税），不送红股，不以公积金转增股本。如果自 2025 年 12 月 31 日至权益分派实施公告确定的股权登记日前，公司 总股本发生变动的，公司将按照分红总金额不变的原则，相应调整每 股分红额。 （二）自利润分配方案披露至实施期间，公司股本总额未发生变 化，因此分配红利总金额及分配比例均不变。 （三）本次实施的权益分派方案与公司 2025 年度股东会审议通 1 山东沃华医药科技股份有限公司 2025 年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 山东沃华医药科技股份有限公司（以下简称公司）2025 年度权 益分派方案已获 20 ...

Group 1 - The core focus of the company is on four exclusive medical insurance products, with outpatient market revenue exceeding 100 million yuan and e-commerce channel sales increasing by 113% year-on-year [1] - The company reported an operating income of 817 million yuan for 2025, a year-on-year increase of 6.96%, and a net profit attributable to shareholders of 95.71 million yuan, a significant increase of 162.93%, marking a ten-year high [2] - The company plans to distribute a cash dividend of 1.46 yuan per 10 shares, totaling approximately 154 million yuan, reflecting a stable financial strategy [2] Group 2 - The stock price of the company has shown volatility over the past seven trading days, closing at 7.28 yuan on February 9, down 0.82%, with a net outflow of 5.228 million yuan in principal funds [3] - As of February 12, the latest stock price was 7.22 yuan, a decrease of 0.96% from the previous day, with a cumulative decline of 0.69% over five days [3] - Trading activity has decreased, with the turnover rate dropping from 3.07% on February 6 to 0.66% on February 12 [3]

Meeting Overview - The shareholders' meeting was convened by the company's board of directors, combining on-site voting and online voting [2][3] - The meeting took place on February 9, 2026, with the on-site meeting starting at 14:00 and online voting available from 9:15 to 15:00 [2][3] Attendance - A total of 244 shareholders attended the meeting, representing 300,230,158 shares, which is 52.0141% of the total voting shares [4] - Among them, 4 shareholders attended on-site, representing 297,938,963 shares (51.6171%), while 240 shareholders participated via online voting, representing 2,291,195 shares (0.3969%) [5][6] Proposals Reviewed and Approved - The following proposals were reviewed and approved during the meeting: - The 2025 Board of Directors' Work Report was approved with 99.9150% of votes in favor [11] - The 2025 Financial Settlement Report was approved with 99.9073% of votes in favor [12] - The 2025 Profit Distribution Plan was approved with 99.9093% of votes in favor, with 89.0420% of small investors voting in favor [13] - The 2025 Annual Report and its summary were approved with 99.9086% of votes in favor [14] - The proposal to reappoint the accounting firm Zhongxi CPA for the 2026 financial audit was approved with 99.8843% of votes in favor, with 86.0147% of small investors voting in favor [15] - The proposal regarding the restructuring of production operations and related transactions was approved with 97.1021% of votes in favor [16][18] Independent Directors' Report - Independent directors submitted their annual performance report, detailing their attendance at board meetings, independent opinions, and suggestions for the company's development [19] Legal Opinions - The meeting was witnessed by lawyers from Beijing Xinghe Law Firm, confirming that the meeting's procedures complied with relevant laws and regulations [19]

关 于 山东沃华医药科技股份有限公司 2025 年度股东会的 法律意见书 北京市星河律师事务所 法律意见书 北京市星河律师事务所 致：山东沃华医药科技股份有限公司 北京市星河律师事务所（以下简称本所）接受山东沃华医药科技股份有限公 司（以下简称贵公司）的委托，就贵公司召开 2025 年度股东会（以下简称本次 会议）的有关事宜，根据《中华人民共和国公司法》（以下简称《公司法》）、 《中华人民共和国证券法》（以下简称《证券法》）、《上市公司股东会规则》 （以下简称《股东会规则》）及《山东沃华医药科技股份有限公司章程》（以下 简称《公司章程》）的有关规定，出具本法律意见书。 为出具本法律意见书，本所委派律师列席了本次会议。本所律师见证了本次 会议的召开全部过程，并对与本次会议召开有关的文件和事实进行了核查和验 证。 本所律师同意将本法律意见书作为贵公司本次股东会公告文件，随其他应当 公告的文件一起向公众披露，并依法对本所律师发表的法律意见承担法律责任。 本所律师根据《公司法》《股东会规则》《公司章程》的有关规定，按照律 师行业公开的标准，道德规范和勤勉尽责的精神，现就本次会议出具法律意见如 下： 一、关于本次会议的 ...

证券代码：002107 证券简称：沃华医药 公告编号：2026-013 山东沃华医药科技股份有限公司 2025 年度股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： （一）本次股东会无增加、否决或修改提案的情况。 3. 会议召开日期和时间： （1）现场会议：2026 年 2 月 9 日（星期一）14：00 （2）网络投票：通过深圳证券交易所交易系统进行网络投票的 具体时间为2026年 2月9 日9:15—9:25，9:30—11:30和 13:00—15:00； 通过深圳证券交易所互联网投票系统进行网络投票的具体时间为 1 2026 年 2 月 9 日 9:15 至 2026 年 2 月 9 日 15:00 的任意时间。 （二）本次股东会不涉及变更前次股东会决议的情况。 一、会议召开和出席情况 （一）会议的召开情况 1. 会议召集人：公司董事会； 2. 会议方式：本次股东会所采用的表决方式是现场表决与网络 投票相结合的方式； 4. 现场会议召开地点：山东省潍坊高新技术产业开发区梨园街 3517 号公司会议室； 5. 现场会议主持人：副 ...

Core Viewpoint - In 2025, Shandong Wohua Pharmaceutical reported a revenue of 817 million yuan, a year-on-year increase of 6.96%, and a net profit of 96 million yuan, a staggering increase of 162.93%. However, the annual report reveals several risk signals, including high sales expenses, unusual inter-subsidiary fund transfers, and governance challenges due to the company's "no actual controller" status [1][7]. Group 1: High Sales Expenses and Fund Transfers - Wohua Pharmaceutical maintained a gross margin of 75.38% in 2025, with its core cardiovascular drugs achieving a gross margin of 83.43%, highlighting the competitiveness of its "exclusive + medical insurance" product matrix [2][8]. - The company incurred sales expenses of approximately 407 million yuan, accounting for nearly 50% of its revenue, raising concerns about compliance risks amid heightened regulatory scrutiny on marketing expenses [2][8]. - The company provided 247 million yuan in loans to its loss-making subsidiary, Liaoning Wohua Kangchen, while its profitable subsidiary, Jiangxi Wohua Jishun, earned 18.54 million yuan, questioning the commercial rationale and safety of such financial support [2][8]. Group 2: Governance Risks from "No Actual Controller" Status - In November 2025, Wohua Pharmaceutical entered a "no actual controller" status due to a court ruling, significantly impacting its governance and decision-making mechanisms [3][10]. - The annual report's disclosure regarding this change was minimal, with critical information placed in less prominent sections, increasing the difficulty for investors to access and understand key governance risks [3][10]. - Compliance experts noted that the reasons and implications of the "no actual controller" status should have been clearly stated in the relevant sections of the report, as this situation could lead to decision-making deadlocks [3][10]. Group 3: Environmental and Climate Disclosure Issues - Wohua Pharmaceutical's environmental performance, particularly regarding wastewater and air emissions, was inadequately reported, with key data not directly listed but linked to external platforms, complicating information access for investors [4][11]. - The company failed to provide any climate-related disclosures, such as risk identification or carbon emission accounting, reflecting a lack of maturity in ESG data management among traditional pharmaceutical companies [5][11]. - The reliance on "link-based disclosure" was criticized as merely meeting formal compliance requirements without providing substantial transparency [4][11]. Conclusion - Wohua Pharmaceutical's 2025 annual report presents a picture of impressive performance but raises concerns regarding governance, compliance, and transparency. As regulatory scrutiny intensifies, the company must address these issues to enhance its governance and disclosure practices [6][12].

Core Insights - The performance of A-share listed companies for 2025 is showing a "polarization" trend, with significant differences in industry prosperity affecting earnings, where some companies achieve substantial profit growth while others, particularly in real estate and photovoltaic sectors, face losses [2][10] Group 1: Earnings Reports - As of January 30, over 70 companies have disclosed their 2025 annual reports, with more than 2200 companies providing earnings forecasts, indicating a clearer market outlook [2][7] - Among the companies that have reported, 51 achieved year-on-year revenue growth, highlighting the resilience of profit growth [3][6] - The top three companies in revenue growth are Shouyao Holdings, Lier Technology, and Xiamen Tungsten, with revenue increases of approximately 120%, 82.97%, and 47.84% respectively [4][5] Group 2: Profit Growth - A total of 47 companies reported year-on-year growth in net profit, with Wohua Pharmaceutical and Lier Chemical showing particularly strong performance, with net profit increases of 162.93% and 122.33% respectively [6] - Wohua Pharmaceutical achieved a revenue of 0.817 billion with a net profit of 0.096 billion, while Lier Chemical reported a revenue of 9.008 billion and a net profit of 0.479 billion [6] Group 3: Earnings Forecasts - Approximately 900 out of 2200 companies that disclosed earnings forecasts are expected to see profit increases, indicating strong growth momentum in the A-share market [7][10] - Notably, over 60 companies anticipate net profit growth exceeding 500%, with 20 companies expecting over 1000% growth, showcasing robust development potential [7][10] - Ningbo Fubang stands out with an expected net profit increase of 3099.59% to 4379.43%, driven by rising silver prices and asset optimization [8][9] Group 4: Loss Predictions - A significant number of companies, particularly in the real estate and photovoltaic sectors, are expected to report losses, with major firms like China Fortune Land Development and Greenland Holdings forecasting losses of 16 billion to 24 billion and 16 billion to 19 billion respectively [10] - The photovoltaic sector is also heavily impacted, with companies like Tongwei and TCL Zhonghuan predicting losses of 9 billion to 10 billion and 8.2 billion to 9.6 billion respectively [10]

山东沃华医药科技股份有限公司（以下简称公司）已于 2026 年 1 月 20 日在巨潮资讯网（http://www.cninfo.com.cn）披露了公司《2025 年度报告》及其摘要。为更好地与广大投资者进行交流，便于投资者 更加深入、全面了解公司生产经营情况，公司拟定于 2026 年 2 月 5 日（星期四）15:00–17:00 举行 2025 年度业绩网上说明会。本次业 绩说明会采用网络远程的方式召开，投资者可登录中证路演中心 （https://www.cs.com.cn/roadshow/）参与本次业绩说明会。 出席公司 2025 年度业绩网上说明会的人员有：副董事长赵彩霞 女士，董事、董事会秘书张戈先生，董事、财务总监王炯先生，独立 董事高明芹女士，总裁李盛廷先生，副总裁曾英姿女士。 为充分尊重投资者，提升与投资者交流的效率和针对性，现就公 司 2025 年度业绩说明会提前向投资者公开征集问题。投资者可于 2026 年 2 月 5 日（星期四）15:00 前登录访问 https://rs.cs.com.cn/dist/#/ask?id=f88107a19563a3a33afd32eb1f780a5 ...